13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity )
Also on site :
- Grandpa of Idaho shooting suspect Wess Roley, 20, breaks his silence as chilling new details emerge about his past
- Rachael Ray Nearly Unrecognizable Amid Fan Concerns About Her Health
- Cruise Passengers Capture 'Miracle' Rescue After 2 Go Overboard: 'Tiny Dots Left Behind in a Massive Ocean'